{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LEXXW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":0.16,"timestamp":1748635200000,"preClose":0.1722,"halted":0,"volume":100,"delay":0,"floatShares":5104300,"shares":5104300,"eps":0,"marketStatus":"Post-Mkt","change":-0.0122,"latestTime":"05-30 19:11:29 EDT","open":0.16,"high":0.16,"low":0.16,"amount":16,"amplitude":0,"askPrice":0.214,"askSize":600,"bidPrice":0.16,"bidSize":400,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1748649600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.1722,"volumeRatio":0.033176},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","floatShares":5104300,"roa":"-77.60%","roe":"-145.55%","lyrEps":0,"volumeRatio":0.033176,"shares":5104300,"dividePrice":0,"high":0.16,"amplitude":0,"preClose":0.1722,"low":0.16,"week52Low":0.15,"pbRate":"0.11","psRate":"1.55","week52High":2,"institutionHeld":0,"latestPrice":0.16,"committee":-0.2,"eps":0,"divideRate":0,"volume":100,"delay":0,"ttmEps":0,"open":0.16,"prevYearClose":0.7641,"prevWeekClose":0.2148,"prevMonthClose":0.3017,"prevQuarterClose":0.3769,"fiveDayClose":0.174,"twentyDayClose":0.2899,"sixtyDayClose":0.2388},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXXW\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490577371","title":"Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5","url":"https://stock-news.laohu8.com/highlight/detail?id=2490577371","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490577371?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:10","pubTimestamp":1733753400,"startTime":"0","endTime":"0","summary":"Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide. KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce the engagement of a contract research organization  to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable liraglutide.As reported on November 20th in Lexaria's 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide - administered orally - demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline. The Rybelsus  control, which was expected to outperform liraglutide, instead produced a 5.65% increase in body weight and 0.41% blood sugar reduction compared to baseline during the same 12 weeks.As a result of the stronger than expected performance of DehydraTECH-processed liraglutide, the Company has made the decision to i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/liraglutide-processed-dehydratech-studied-human-141000375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","GLP","BK4144","LEXX","BK4590"],"gpt_icon":0},{"id":"2489629274","title":"LEXX: Phase I Start Imminent","url":"https://stock-news.laohu8.com/highlight/detail?id=2489629274","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489629274?lang=en_us&edition=fundamental","pubTime":"2024-12-05 19:15","pubTimestamp":1733397300,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corporation  reported fiscal third 2024 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the total to 43. Lexaria’s primary focus for fiscal 2024 was to demonstrate that DehydraTECH  can be an effective delivery system serving the burgeoning GLP-1 agonist space. Oral options for GLP-1s are limited and initial data for DHT-GLP-1s promising leading to the development of a series of studies that seek to find the best approach for a more convenient delivery method. At the end of August, Lexaria completed its 2024 fiscal year and reported these results at the end of November. We summarize the results below.Lexaria filed its 2024 Form 10-K on November 26th, 2024. The company reported FY 2024 revenues of $464,000, and total operating expense of $6.2 million resulting in net loss of  million or  per diluted common ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Mp_Fa5DFH7PuFiLoGgWpJg--~B/aD04ODY7dz0xMzYyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/9843c2749db06147b1cb8e87941c5dce","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Mp_Fa5DFH7PuFiLoGgWpJg--~B/aD04ODY7dz0xMzYyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/9843c2749db06147b1cb8e87941c5dce"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexx-phase-start-imminent-111500537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACB","LEXXW","LEXX","BK4557","DHT","BK4007","BK4144"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXXW\",market:\"US\",delay:false,,,undefined,":{}}}